Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 7582730, 15 pages
Review Article

Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib

1Laboratory of Pathophysiology of Cachexia and Metabolism of Skeletal Muscle, IRCCS San Raffaele Pisana, 00166 Rome, Italy
2Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
3Bionem Laboratory, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy
4Cardiovascular and Cell Sciences Institute, St George’s, University of London, Cranmer Terrace, London, UK

Correspondence should be addressed to Elisabetta Ferraro; ti.eleaffarnas@orarref.attebasile

Received 3 November 2017; Revised 23 January 2018; Accepted 6 February 2018; Published 18 March 2018

Academic Editor: Vladimir Jakovljevic

Copyright © 2018 Stefania Gorini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Stefania Gorini, Antonella De Angelis, Liberato Berrino, Natalia Malara, Giuseppe Rosano, and Elisabetta Ferraro, “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 7582730, 15 pages, 2018.